JP4873825B2 - ウロコルチン蛋白質及びその利用 - Google Patents

ウロコルチン蛋白質及びその利用 Download PDF

Info

Publication number
JP4873825B2
JP4873825B2 JP2002518278A JP2002518278A JP4873825B2 JP 4873825 B2 JP4873825 B2 JP 4873825B2 JP 2002518278 A JP2002518278 A JP 2002518278A JP 2002518278 A JP2002518278 A JP 2002518278A JP 4873825 B2 JP4873825 B2 JP 4873825B2
Authority
JP
Japan
Prior art keywords
urocortin
crf
human
dna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002518278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505640A5 (https=
JP2004505640A (ja
Inventor
ヴエイル，ワイリ，ダブリュ．
ソウチェンコ，ポール，エフ．
ルイス，キャシイ，エイ．
ヴォーン，ジョウン，エム．
レイズ，テレサ，エム．
リビエール，ジーン，イー．
ホウグネッシュ，ジョウン，ビィ．
ペリン，マリリン，エイチ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of JP2004505640A publication Critical patent/JP2004505640A/ja
Publication of JP2004505640A5 publication Critical patent/JP2004505640A5/ja
Application granted granted Critical
Publication of JP4873825B2 publication Critical patent/JP4873825B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
JP2002518278A 2000-08-04 2001-07-31 ウロコルチン蛋白質及びその利用 Expired - Fee Related JP4873825B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22325500P 2000-08-04 2000-08-04
US60/223,255 2000-08-04
US27396901P 2001-03-07 2001-03-07
US60/273,969 2001-03-07
PCT/US2001/023976 WO2002012307A1 (en) 2000-08-04 2001-07-31 Urocortin proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2004505640A JP2004505640A (ja) 2004-02-26
JP2004505640A5 JP2004505640A5 (https=) 2008-09-25
JP4873825B2 true JP4873825B2 (ja) 2012-02-08

Family

ID=26917597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002518278A Expired - Fee Related JP4873825B2 (ja) 2000-08-04 2001-07-31 ウロコルチン蛋白質及びその利用

Country Status (16)

Country Link
US (4) US6838274B2 (https=)
EP (1) EP1305334B1 (https=)
JP (1) JP4873825B2 (https=)
KR (1) KR100879232B1 (https=)
CN (1) CN1484650B (https=)
AT (1) ATE408622T1 (https=)
AU (2) AU2001284683B2 (https=)
CA (1) CA2418144C (https=)
CY (1) CY1110424T1 (https=)
DE (1) DE60135850D1 (https=)
DK (1) DK1305334T3 (https=)
ES (1) ES2313978T3 (https=)
IL (2) IL154102A0 (https=)
PT (1) PT1305334E (https=)
RU (1) RU2278871C2 (https=)
WO (1) WO2002012307A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1305334T3 (da) * 2000-08-04 2009-02-02 Res Dev Foundation Urocortinproteiner og anvendelser deraf
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6812210B2 (en) 2001-03-15 2004-11-02 Research Development Foundation Urocortin-III and uses thereof
US7192924B2 (en) 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
US7982018B2 (en) * 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
WO2008157302A2 (en) 2007-06-13 2008-12-24 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
AU2008297411A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100204113A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
WO2011025905A1 (en) * 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
CN108310396B (zh) 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
CN110826145B (zh) * 2019-09-09 2020-08-28 西安工业大学 基于超启发式马氏链进化的汽车多参数运行工况设计方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0845035A2 (en) 1995-06-13 1998-06-03 The Salk Institute For Biological Studies Urocortin peptides
DK1305334T3 (da) * 2000-08-04 2009-02-02 Res Dev Foundation Urocortinproteiner og anvendelser deraf
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
IL154102A0 (en) 2003-07-31
IL154102A (en) 2010-12-30
EP1305334B1 (en) 2008-09-17
RU2003105897A (ru) 2005-01-20
CY1110424T1 (el) 2015-04-29
ES2313978T3 (es) 2009-03-16
US20100168021A1 (en) 2010-07-01
US20020127221A1 (en) 2002-09-12
WO2002012307A1 (en) 2002-02-14
CN1484650B (zh) 2012-12-12
ATE408622T1 (de) 2008-10-15
DE60135850D1 (de) 2008-10-30
US6838274B2 (en) 2005-01-04
US7223846B2 (en) 2007-05-29
DK1305334T3 (da) 2009-02-02
AU2001284683B2 (en) 2006-04-27
US8044025B2 (en) 2011-10-25
EP1305334A4 (en) 2005-03-23
RU2278871C2 (ru) 2006-06-27
AU8468301A (en) 2002-02-18
KR100879232B1 (ko) 2009-01-20
EP1305334A1 (en) 2003-05-02
US7638607B2 (en) 2009-12-29
PT1305334E (pt) 2008-12-30
KR20030074589A (ko) 2003-09-19
CA2418144A1 (en) 2002-02-14
CA2418144C (en) 2013-06-18
US20070191592A1 (en) 2007-08-16
CN1484650A (zh) 2004-03-24
JP2004505640A (ja) 2004-02-26
US20050191650A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
US8044025B2 (en) Urocortin proteins and uses thereof
US9388229B2 (en) Urocortin-III and uses thereof
AU2001284683A1 (en) Urocortin proteins and uses thereof
AU2002306853A1 (en) Urocortin-III and uses thereof
NZ523803A (en) Human urocortin-related polypeptide (URP) and uses thereof to rreat a pathophysiological state, eg stress, anxiety and appetite dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080728

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080728

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111102

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111122

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4873825

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees